Drug Delivery
To ensure that biotechnologically produced drugs are not recognized as foreign by the immune system and eliminated prematurely from the body, biotechnology uses different methods for modifying them so that effective drug delivery is possible.
celares gmbh is specialized in modifying biopharmaceuticals with polyethylene glycols (PEG), through which active ingredients have a longer effect in the body and are more soluble. Whereas in this technology the ingredients are chemically coupled with PEG, Alrise Biosystems GmbH encapsulates biotechnological ingredients with a microparticle envelope. This envelope prevents the drugs from decomposing in the liver, but instead allows them to be released in a controlled manner into the body.
The above technologies not only reduce side effects; the drugs also need to be taken less frequently.
Drug delivery is not only interesting for newly developed substances: Biopharmaceuticals already on the market can gain new patent protection with the aid of a new form of administration.
News innovation
Talk in the Cube: IP STRATEGIES IN BIOTECHNOLOGY
We are excited to continue the Talks in the Cube with an expert discussion focused on Strategies for Intellectual Property Rights in Biotechnology.
more ...Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation Radiopharmaceutical ART-101
Eckert & Ziegler (ISIN DE0005659700) has entered a Master Service Agreement with Archeus Technologies (Archeus), a company developing multiple differentiated radiopharmaceutical therapies, for contrac...
more ...Eckert & Ziegler: Capital Increase Entered in the Commercial Register. Share Split in Preparation.
The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) resolved on June 18, 2025, to increase the share capital using company funds by € 42,343,864 to € 63,515,796.
more ...
